<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article70</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/COGENT" style="display:block; margin-bottom:10px;">COGENT Original</a></li>
<h2><strong>COGENT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Clopidogrel with or without Omeprazole in Coronary Artery Disease". The New England Journal of Medicine. 2010.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does the addition of a proton-pump inhibitor (PPI) to dual antiplatelet therapy with aspirin and clopidogrel reduce gastrointestinal complications without increasing cardiovascular events?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding without significantly increasing cardiovascular events. However, the study's premature termination limits the conclusiveness regarding cardiovascular safety.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
No guidelines were specified reflecting the results of this trial at the time of publication.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, parallel-group, randomized, placebo-controlled trial<br/>
- N=3,873 patients with indications for dual antiplatelet therapy<br/>
- Randomized to clopidogrel with either omeprazole or placebo, in addition to aspirin<br/>
- Trial prematurely terminated due to sponsor's financial issues<br/>
- Median follow-up: 106 days (max 341 days)<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Inclusion criteria: Patients â‰¥21 years, indication for dual antiplatelet therapy for at least 12 months<br/>
- Exclusion criteria: Need for PPIs, H2-receptor antagonists, or certain anti-inflammatory drugs; recent fibrinolytic therapy<br/>
- Baseline characteristics: Well-matched between treatment groups<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- CGT-2168 (fixed-dose combination of clopidogrel 75 mg and omeprazole 20 mg) vs. clopidogrel alone<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary gastrointestinal end point: Composite of overt/occult bleeding, symptomatic gastroduodenal ulcers or erosions, obstruction, or perforation<br/>
- Primary cardiovascular end point: Composite of death from cardiovascular causes, nonfatal myocardial infarction, revascularization, or stroke<br/>
- Notable secondary end point: Symptoms of gastroesophageal reflux disease<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Premature termination meant smaller number of events, limiting power<br/>
- Wide confidence intervals for the cardiovascular end point, so no significant interaction could be considered conclusive<br/>
- The use of a single-pill formulation with different release kinetics from generic omeprazole<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Cogentus Pharmaceuticals; trial ended prematurely when the sponsor became defunct.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- ClinicalTrials.gov number, NCT00557921
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
